Solvent/detergent treatment of platelet concentrates enhances the release of growth factors
- 25 March 2008
- journal article
- Published by Wiley in Transfusion
- Vol. 48 (6), 1090-1098
- https://doi.org/10.1111/j.1537-2995.2008.01691.x
Abstract
Platelet (PLT) growth factors released by thrombin activation of autologous PLT concentrates (PCs) are used in clinics as PLT gels or releasates for tissue repair and wound healing applications. If allogeneic products are to be used for clinical or cell culture applications, a method of viral inactivation of the PC source of growth factors is desirable.PLT-derived growth factor-AB (PDGF-AB), transforming growth factor-beta1 (TGF-beta1), epidermal growth factor (EGF), and insulinlike growth factor-1 (IGF-1) in apheresis PC subjected to solvent/detergent (S/D) treatment with or without prior activation by CaCl(2) and/or bovine thrombin were measured.Mean (+/- standard deviation) PDGF-AB, TGF-beta1, EGF, and IGF-1 content was 13.8 +/- 14.3, 16.6 +/- 14.3, less than 0.0007, and 83.4 +/- 33.4 ng per mL, respectively, in the starting PC. They increased to 184.4 +/- 80.2, 192.2 +/- 37.4, 2.2 +/- 1.6, and 88.4 +/- 33.5 after 1 percent tri-n-butyl phosphate (TnBP)-1 percent Triton X-45 treatment, respectively. Mean content was 84.6 +/- 35.5, 63.8 +/- 14.1, 0.9 +/- 0.6, and 117.2 +/- 34.9 ng per mL, respectively, in CaCl(2)-activated PC and remained stable after subsequent S/D treatment (88.3 +/- 45.9, 68.6 +/- 27.2, 1.40 +/- 1.0, and 112.4 +/- 39.7 ng/mL, respectively). Two percent TnBP treatment yielded similar release as with TnBP-Triton X-45. Addition of bovine thrombin did not increase the release of growth factors.S/D treatment efficiently releases PDGF-AB, TGF-beta1, and EGF from nonactivated apheresis PCs and may be of interest to prepare virally inactivated allogeneic growth factors for clinical and cell culture applications.Keywords
This publication has 33 references indexed in Scilit:
- Pathogen InactivationAmerican Journal of Clinical Pathology, 2007
- Pathogen inactivation: making decisions about new technologiesTransfusion, 2007
- Platelet‐rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point?ISBT Science Series, 2007
- A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable‐bag systemTransfusion, 2006
- Platelet gels and releasatesCurrent Opinion in Hematology, 2005
- Pathogen inactivation technology: cleansing the blood supplyJournal of Internal Medicine, 2005
- Abundant Retention and Release of Connective Tissue Growth Factor (CTGF/CCN2) by PlateletsThe Journal of Biochemistry, 2004
- Platelet-derived growth factor-AB and transforming growth factor-β1 in platelet gels activated by single-donor human thrombinTransfusion, 2004
- Autologous platelets as a source of proteins for healing and tissue regenerationThrombosis and Haemostasis, 2004
- Bone growth factors in maxillofacial skeletal reconstructionInternational Journal of Oral & Maxillofacial Surgery, 2002